Portal Hypertension in the 21st Century, Softcover reprint of the original 1st ed. 2004 The proceedings of a symposium sponsored by Axcan Pharma Inc. and NicOx S.A., held in Montrél, Canada, April 2–4, 2004

Langue : Anglais

Coordonnateurs : Groszmann R.J., Bosch J.

Couverture de l’ouvrage Portal Hypertension in the 21st Century

Résumé
Sommaire

Portal hypertension is the most important complication of a great variety of both acute and chronic liver diseases. Nevertheless, hepatic cirrhosis is the most frequent cause of portal hypertension. Gastrointestinal bleeding due to rupture of oesophageal varices is, without doubt, the most severe complication of portal hypertension. At present, great advances are being made in the pathophysiology and in the development of new therapeutic tools for controlling and preventing this severe clinical event.

This book contains the papers presented and discussed during the Symposium on 'Portal Hypertension in the 21st Century', held in Montréal, Canada, in April 2004, and sponsored by Axcan Pharma Inc. and NicOx S.A. There are eight sections covering basic mechanisms, new drugs, prevention and current treatment of variceal bleeding, prevention of recurrent bleeding and hepatic hemodynamic monitoring.

An international faculty of authors have contributed chapters at an outstanding scientific level which will be vital reading for scientists and clinicians alike.

1 Portal hypertensive syndrome: its importance and complications.- 2 The vascular endothelium and nitric oxide.- 3 Endothelial-derived nitric oxide as a marker for healthy endothelium.- 4 Mechanisms of hepatic fibrogenesis.- 5 The role of hepatic stellate cells/myofibroblasts.- 6 Structural changes in the liver leading to cirrhosis and portal hypertension.- 7 The paradox: vasoconstriction and vasodilation.- 8 Nitric-oxide-mediated vasodilation and portal hypertension.- 9 Impaired vasodilation in cirrhotic livers.- 10 Enhanced release of vasoconstrictors.- 11 Endogenous cannabinoids and circulatory dysfunction in cirrhosis.- 12 NCX-1105: a liver-specific NO donor.- 13 Possibilities of manipulating NO biosynthesis in the treatment of portal hypertension: statins.- 14 Pathophysiological role of Akt and endothelial nitric oxide synthase in cirrhosis.- 15 Nitric oxide synthase gene transfer.- 16 Inhibition of nitric-oxide-mediated vasodilation (including K+ channels).- 17 Esophageal varices: from appearance to rupture; natural history and prognostic indicators.- 18 Pathophysiology of variceal bleeding.- 19 Approaches to the management of pediatric portal hypertension: results of an informal survey.- 20 Therapeutic tools in portal hypertension: drugs.- 21 Endoscopy in the management of portal hypertension.- 22 Transjugular intrahepatic portosystemic shunt (TIPS): current indications.- 23 Prevention of first variceal bleeding: drugs.- 24 Prevention of first variceal bleeding: endoscopy.- 25 Treatment of acute variceal bleeding: general management and prevention of infections.- 26 Hemostatic treatments.- 27 Prevention of recurrent portal hypertensive bleeding.- 28 Cost-effectiveness of primary prophylaxis for esophageal variceal bleeding.- 29 The cirrhotic patient with no varices and with small varices.- 30 Gastric varices.- 31 The patient who cannot receive beta-blockers.- 32 Hepatic venous pressure gradient: the facts.- 33 Hemodynamic monitoring: implications for randomized controlled trials and clinical practice.- 34 What to do with non-responders.- 35 What else we need.